Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 26, Issue 146, 2017, Pages

  Lancaster, Lisa H ^a   de Andrade, Joao A ^b   Zibrak, Joseph D ^c   Padilla, Maria L ^d   Albera, Carlo ^e   Nathan, Steven D ^f   Wijsenbeek, Marlies S ^g   Stauffer, John L ^h   Kirchgaessler, Klaus Uwe ⁱ   Costabel, Ulrich ^j  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Mount Sinai National Jewish Health Respiratory Institute   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h GENENTECH INC   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PIRFENIDONE; PLACEBO; STEROID; SULFADIAZINE SILVER; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANOREXIA; BLEEDING; BRONCHITIS; COMORBIDITY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ELDERLY CARE; FATIGUE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GRAFT DYSFUNCTION; HEADACHE; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LOSS OF APPETITE; LUNG DIFFUSION CAPACITY; LUNG TRANSPLANTATION; MAINTENANCE DRUG DOSE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PHOTOSENSITIVITY; PHOTOTOXICITY; PREVENTIVE MEDICINE; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN PROTECTION; SKIN TOXICITY; SUN EXPOSURE; TREATMENT DURATION; TREATMENT INTERRUPTION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; CONVALESCENCE; DISEASE FREE SURVIVAL; DRUG EFFECT; LUNG; MEDICATION COMPLIANCE; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE-FREE SURVIVAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MEDICATION ADHERENCE; PYRIDONES; RECOVERY OF FUNCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85037611609     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0057-2017     Document Type: Review

References (52)

1. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129-137.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
3. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011; 140: 221-229.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
5. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013; 5: 483-492.
6. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014; 2: 566-572.
7. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795-806.
8. Esbriet (pirfenidone) capsules, for oral use. Package insert. San Francisco, Genentech, Inc., 2017.
9. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
10. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
11. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
12. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
13. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2017; 5: 33-41.
14. Nathan SD, Albera C, Costabel U, et al. Effect of continued pirfenidone treatment following a ⩾15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): pooled analysis from 3 pivotal studies. Eur Respir J 2016; 48: Suppl 60, OA1765.
15. King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014; 189: 825-831.
16. Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224-226.
17. Loeh B, Drakopanagiotakis F, Bandelli GP, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 191: 110-113.
18. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
19. Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther 2015; 32: 691-704.
20. Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016; 3: e000105.
21. Lancaster L, Morrison L, Auais A, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis in a US expanded access program. Am J Respir Crit Care Med 2016; 193: A2695.
22. Cottin V, Maher TM, Azuma A, et al. Pirfenidone post-authorization safety registry (PASSPORT) update. Eur Respir J 2015; 46: Suppl 59, OA4500.
23. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198-205.
24. Costabel U, Albera C, Lancaster LH, et al. Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2016; 48: Suppl 60, OA1812.
25. Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016; 4: 445-453.
26. Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 2016; 43: 1672-1679.
27. Savarino E, Furnari M, de Bortoli N, et al. Gastrointestinal involvement in systemic sclerosis. Presse Med 2014; 43: e279-e291.
28. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747.
29. Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 58-64.
30. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-747.
31. Mason WR, Nathan SD, Zibrak JD, et al. Time-to-event analysis of common adverse events with pirfenidone in patients with IPF-a pooled analysis of three phase III clinical trials. Am J Respir Crit Care Med 2017; 195: A6798.
32. Nathan SD, Lancaster LH, Albera C, et al. Dose modifications and dose intensity during treatment with pirfenidone. Eur Respir J 2016; 48: Suppl 60, OA1764.
33. Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016; 5: E78.
34. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31: 375-391.
35. Shi S, Wu J, Chen H, et al. Single-and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 2007; 47: 1268-1276.
36. Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009; 22: 279-285.
37. King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2015; 21: 479-489.
38. The Voice of the Patient: A Series of Reports from the US Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative. Idiopathic Pulmonary Fibrosis. Silver Spring, US Food and Drug Administration, 2015. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM440829.pdf
39. Salih GN, Shaker SB, Madsen HD, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J 2016; 3: 32608.
40. Ley B, Collard HR. Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 6-7.
41. Meyer KC, Danoff SK, Lancaster LH, et al. Management of idiopathic pulmonary fibrosis in the elderly patient: addressing key questions. Chest 2015; 148: 242-252.
42. Lancaster LH, Morrison LD, Auais A, et al. Pirfenidone in patients aged 80 years and older with idiopathic pulmonary fibrosis (IPF): safety findings from pooled trial databases. Am J Respir Crit Care Med 2017; 195: A5385.
43. Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711. L (PEOPLE Study). Respir Res 2016; 17: 90.
44. Delanote I, Wuyts WA, Yserbyt J, et al. Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulm Med 2016; 16: 156.
45. Mortensen A, Cherrier L, Walia R. Lung transplantation on pirfenidone: a single center experience. J Heart Lung Transplant 2016; 35: Suppl., S302, abstract 833.
46. Riddell P, Minnis P, Ging P, et al. Pirfenidone as a bridge to lung transplantation in patients with progressive IPF. Thorax 2014; 69: A183.
47. Ihle F, von Wulffen W, Neurohr C. Pirfenidone: a potential therapy for progressive lung allograft dysfunction? J Heart Lung Transplant 2013; 32: 574-575.
48. Noble PW, Albera C, Kirchgaessler KU, et al. Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment. Eur Respir J 2016; 48: Suppl 60, OA1809.
49. Costabel U, Albera C, Kirchgaessler K, et al. Analysis of patients with idiopathic pulmonary fibrosis (IPF) with more severe lung function impairment treated with pirfenidone in RECAP. Chest 2016; 150: 537A.
50. Gali JA, Pandya A, Vega-Olivio M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in real-world clinical practice: tolerability and adverse drug reactions. Am J Respir Crit Care Med 2016; 193: A2604.
51. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11: e0151425.
52. Glassberg MK, Nathan SD, Lin CY, et al. Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2016; 193: A4980.